citalopram has been researched along with Agoraphobia in 10 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Agoraphobia: Obsessive, persistent, intense fear of open places.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of a short treatment (7 days) with citalopram on the reactivity to inhalations of 35% CO2 and 65% oxygen and on clinical symptomatology was investigated in 15 patients with panic disorder who had a positive response to 35% CO2 inhalation." | 9.09 | The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. ( Bellodi, L; Bertani, A; Bussi, R; Caldirola, D; Perna, G, 2001) |
| "The current trial is a second-step stratified randomized design comparing two treatment conditions-selective serotonin reuptake inhibitor (SSRI; paroxetine or citalopram; n = 34) and continued CBT (n = 24)-in a sample of individuals classified as treatment nonresponders to an initial course of CBT for panic disorder." | 5.22 | SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL. ( Barlow, DH; Farchione, TJ; Gallagher, MW; Gorman, JM; Payne, LA; Shear, MK; White, KS; Woods, SW, 2016) |
| "We aimed to examine whether anxiety sensitivity and agoraphobic fear could affect the time taken to remission after 24 weeks of open-label escitalopram treatment of patients with panic disorder (PD)." | 5.16 | Psychological characteristics of early remitters in patients with panic disorder. ( Chung, SK; Kang, EH; Kim, EJ; Kim, JH; Kim, YR; Ku, JI; Lee, JH; Lee, SH; Lee, SY; Park, HJ; Woo, JM; Yu, BH, 2012) |
| " The patients were assessed on measures of interpretative bias (homophone task), anxiety and depression before being prescribed an SSRI (paroxetine or citalopram)." | 5.11 | Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. ( Baldwin, DS; Bradley, BP; Brodrick, P; Mogg, K, 2004) |
| "The effect of a short treatment (7 days) with citalopram on the reactivity to inhalations of 35% CO2 and 65% oxygen and on clinical symptomatology was investigated in 15 patients with panic disorder who had a positive response to 35% CO2 inhalation." | 5.09 | The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. ( Bellodi, L; Bertani, A; Bussi, R; Caldirola, D; Perna, G, 2001) |
| "Treatment with citalopram resulted in a gradual decline of anxiety symptoms." | 1.32 | Alexithymia in Noonan syndrome. ( Egger, JI; Hendrikx, JL; MDoorakkers, MC; Tuinier, S; Van der Burgt, I; Verhoeven, WM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Payne, LA | 1 |
| White, KS | 1 |
| Gallagher, MW | 1 |
| Woods, SW | 1 |
| Shear, MK | 1 |
| Gorman, JM | 1 |
| Farchione, TJ | 1 |
| Barlow, DH | 1 |
| Benvenuti, A | 1 |
| Rucci, P | 1 |
| Calugi, S | 1 |
| Cassano, GB | 1 |
| Miniati, M | 1 |
| Frank, E | 1 |
| Park, HJ | 1 |
| Kim, EJ | 1 |
| Ku, JI | 1 |
| Woo, JM | 1 |
| Lee, SH | 1 |
| Chung, SK | 1 |
| Lee, SY | 1 |
| Kim, YR | 1 |
| Kang, EH | 1 |
| Lee, JH | 1 |
| Kim, JH | 1 |
| Yu, BH | 1 |
| Perna, G | 2 |
| Alpini, D | 1 |
| Caldirola, D | 2 |
| Raponi, G | 1 |
| Cesarani, A | 1 |
| Bellodi, L | 2 |
| Verhoeven, WM | 1 |
| Hendrikx, JL | 1 |
| MDoorakkers, MC | 1 |
| Egger, JI | 1 |
| Van der Burgt, I | 1 |
| Tuinier, S | 1 |
| Mogg, K | 1 |
| Baldwin, DS | 1 |
| Brodrick, P | 1 |
| Bradley, BP | 1 |
| Marchesi, C | 1 |
| Cantoni, A | 1 |
| Fontò, S | 1 |
| Giannelli, MR | 1 |
| Maggini, C | 1 |
| Warwick, JM | 1 |
| Carey, P | 1 |
| Van der Linden, G | 1 |
| Prinsloo, C | 1 |
| Niehaus, D | 1 |
| Seedat, S | 1 |
| Dupont, P | 1 |
| Stein, DJ | 1 |
| Bertani, A | 1 |
| Bussi, R | 1 |
| Humble, M | 1 |
| Wistedt, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Panic Disorder: Long Term Strategies[NCT00000368] | Phase 3 | 379 participants (Actual) | Interventional | 1999-02-28 | Completed | ||
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for citalopram and Agoraphobia
| Article | Year |
|---|---|
Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders.
Topics: Adult; Agoraphobia; Citalopram; Dose-Response Relationship, Drug; Drug Administration Schedule; Fema | 1992 |
6 trials available for citalopram and Agoraphobia
| Article | Year |
|---|---|
SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL.
Topics: Adult; Agoraphobia; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Hum | 2016 |
Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression.
Topics: Adult; Affect; Agoraphobia; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorde | 2010 |
Psychological characteristics of early remitters in patients with panic disorder.
Topics: Adult; Agoraphobia; Anxiety; Citalopram; Female; Humans; Male; Panic Disorder; Psychiatric Status Ra | 2012 |
Serotonergic modulation of the balance system in panic disorder: an open study.
Topics: Adult; Agoraphobia; Citalopram; Dose-Response Relationship, Drug; Drug Administration Schedule; Fema | 2003 |
Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder.
Topics: Adult; Affect; Agoraphobia; Citalopram; Cognition; Cross-Sectional Studies; Depression; Female; Huma | 2004 |
The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Second-Generation; Carbon Dioxide; Citalopram | 2001 |
3 other studies available for citalopram and Agoraphobia
| Article | Year |
|---|---|
Alexithymia in Noonan syndrome.
Topics: Abnormalities, Multiple; Adult; Affective Symptoms; Agoraphobia; Chromosomes, Human, Pair 12; Citalo | 2004 |
Predictors of symptom resolution in panic disorder after one year of pharmacological treatment: a naturalistic study.
Topics: Adult; Agoraphobia; Anxiety Disorders; Citalopram; Diagnostic and Statistical Manual of Mental Disor | 2006 |
A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder.
Topics: Adult; Agoraphobia; Antidepressive Agents; Brain; Cerebrovascular Circulation; Citalopram; Female; H | 2006 |